<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00536887</url>
  </required_header>
  <id_info>
    <org_study_id>CFR</org_study_id>
    <nct_id>NCT00536887</nct_id>
  </id_info>
  <brief_title>Effects of Atorvastatin 10 mg Versus 40 mg in Eight Months Follow-up Coronary Flow Reserve and Bone Marrow Stem Cell Mobilization in Patients With Acute Myocardial Infarction</brief_title>
  <official_title>Phase 4 Study of Atorvastatin 10mg vs. 40mg in Follow-up CFR in AMI Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea University Anam Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea University Anam Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many data indicate that statins increase mobilization of bone marrow-derived stem cells, and&#xD;
      circulating bone marrow-derived stem cells are capable of homing to sites of myocardial&#xD;
      infarction and endothelial disruption, thereby restoring myocardial function and&#xD;
      microvascular integrity after acute myocardial infarction. Atorvastatin is widely used in the&#xD;
      treatment of hyperlipidemia, especially after acute myocardial infarction. High-dose&#xD;
      atorvastatin has been known to stop the progression of atherosclerosis and to decrease the&#xD;
      levels of inflammatory markers.&#xD;
&#xD;
      The purpose of this prospective, randomized, single-blinded trial is to compare the effect of&#xD;
      atorvastatin 10 mg versus 40 mg in restoring coronary flow reserve (CFR) and in serial bone&#xD;
      marrow stem cell mobilization during the 8 months follow-up in patients with acute myocardial&#xD;
      infarction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Percutaneous coronary intervention is considered as the gold standard for primary treatment&#xD;
      after acute myocardial infarction, and clinical outcome and recovery of myocardial&#xD;
      contractility after successful coronary intervention are influenced by the extent of&#xD;
      microvascular damage. The use of intracoronary Doppler evaluation of infarct-related coronary&#xD;
      artery allows direct assessment of microvascular integrity after acute myocardial infarction.&#xD;
      The assessment of coronary flow reserve should be performed at least 24 hours after acute&#xD;
      myocardial infarction, and we will evaluate coronary flow reserve 5 days after acute&#xD;
      myocardial infarction. Intracoronary Doppler wire will be placed just distal to the stent,&#xD;
      and intracoronary Doppler assessment is repeated 8 months after coronary stenting at the same&#xD;
      point.&#xD;
&#xD;
        1. Primary end point: Comparison of atorvastatin 10 mg versus 40 mg on 8 months follow-up&#xD;
           coronary flow reserve (CFR) and on the serial changes in stem cell mobilization (CD34,&#xD;
           CD117, CD133, CXCR4+, C-met) after acute myocardial infarction.&#xD;
&#xD;
        2. Secondary end point: Comparison of atorvastatin 10 mg versus 40 mg on the changes in the&#xD;
           levels of inflammatory markers (hsCRP, IL-6, TNF-α, adiponectin) and on the clinical&#xD;
           events such as cardiac death, myocardial infarction, target vessel revascularization&#xD;
           during the 8 months of follow-up.&#xD;
&#xD;
      1) Study design&#xD;
&#xD;
        -  Prospective, randomized, single-blinded study.&#xD;
&#xD;
        -  Patients enrollment: 100 patients (50 patients in each group) considering 20% drop-out&#xD;
           rate.&#xD;
&#xD;
        -  After informed consent, patients will be randomly assigned to the Atorvastatin 10 mg&#xD;
           Group or the Atorvastatin 40 mg Group.&#xD;
&#xD;
           2) Study protocol&#xD;
&#xD;
        -  After IRB approval, we will enroll within 10 months 100 acute myocardial infarction&#xD;
           patients requiring stent implantation.&#xD;
&#xD;
        -  Study follow-up period will be 8 months.&#xD;
&#xD;
        -  Baseline clinical, laboratory, and angiographic parameters will be obtained at baseline&#xD;
           and at 8 months follow-up. Out-patients follow-up will be scheduled at 4 weeks, 16&#xD;
           weeks, 32 weeks after sirolimus-eluting stent implantation.&#xD;
&#xD;
        -  We will compare atorvastatin 10 mg versus atorvastatin 40 mg on the changes in coronary&#xD;
           flow reserve during the 8 months of follow-up. The serial changes (baseline, 24 hours,&#xD;
           48 hours, 5 days, 8 months) in stem cell mobilization (CD34, CD117, CD133, CXCR4+,&#xD;
           C-met) will be compared in addition to major adverse cardiac events (cardiac death,&#xD;
           myocardial infarction, target vessel revascularization) and inflammatory markers (hsCRP,&#xD;
           IL-6, TNF-α, adiponectin).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of atorvastatin 10 mg versus 40 mg on 8 months follow-up coronary flow reserve (CFR) and on the serial changes in stem cell mobilization (CD34, CD117, CD133, CXCR4+, C-met) after acute myocardial infarction.</measure>
    <time_frame>8 month follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of atorvastatin 10 mg versus 40 mg on the changes in the levels of inflammatory markers (hsCRP, IL-6, TNF-α, adiponectin) and on the clinical events such as cardiac death, myocardial infarction, target vessel revascularization during the 8 mon</measure>
    <time_frame>8 months follow-up</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atorvastatin</intervention_name>
    <description>atorvastatin 10 mg versus 40 mg during the 8 months of follow-up</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years and above&#xD;
&#xD;
          -  Gender eligible for study both&#xD;
&#xD;
          -  Patients with acute myocardial infarction requiring sirolimus-eluting stent&#xD;
             implantation&#xD;
&#xD;
          -  Acute myocardial infarction affecting proximal to mid coronary arteries&#xD;
&#xD;
          -  No lesions greater than 50 percent diameter stenosis distal to the stent implantation&#xD;
&#xD;
          -  Patients with informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Left main lesion&#xD;
&#xD;
          -  Killip Class IV acute myocardial infarction&#xD;
&#xD;
          -  Patients with current use of any statin&#xD;
&#xD;
          -  Tortuous lesion with difficult intracoronary Doppler wiring&#xD;
&#xD;
          -  Acute myocardial infarction affecting distal coronary arteries&#xD;
&#xD;
          -  Acute myocardial infarction affecting branching coronary arteries&#xD;
&#xD;
          -  The use of thiazolidinediones within 3 months&#xD;
&#xD;
          -  Previous history of PCI or bypass surgery on infarct-related coronary artery&#xD;
&#xD;
          -  Patients with any contraindications to the treatment of atorvastatin&#xD;
&#xD;
          -  Pregnant or lactating patients&#xD;
&#xD;
          -  Chronic alcohol or drug abuse&#xD;
&#xD;
          -  Hepatic dysfunction (3 times above upper normal limit 5 days after AMI)&#xD;
&#xD;
          -  Renal dysfunction (Creatinine greater than 2.0 mg/dL)&#xD;
&#xD;
          -  Severe Heart failure (EF less than 25 percent)&#xD;
&#xD;
          -  Expected life expectancy of less thna 1 year&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Soon Jun Hong, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Anam Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sang Yup Lim, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Korea University Anam Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>136-705</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <study_first_submitted>September 27, 2007</study_first_submitted>
  <study_first_submitted_qc>September 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2007</study_first_posted>
  <last_update_submitted>April 6, 2012</last_update_submitted>
  <last_update_submitted_qc>April 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 9, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Korea University Anam Hospital</investigator_affiliation>
    <investigator_full_name>Soon Jun Hong</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

